BRISTOL-MYERS SQUIBB COMPANY Total Liabilities
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Total Liabilities of $65.31 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-07-30
- 2026-06-30: Liabilities $65.31B.
- 2026-03-31: Liabilities $66.37B.
- 2025-12-31: Liabilities $71.53B.
- 2025-09-30: Liabilities $78.29B.
| Period end | Liabilities |
|---|---|
| 2026-06-30 | $65.31B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $66.37B 10-Q · filed 2026-04-30 |
| 2025-12-31 | $71.53B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $78.29B 10-Q · filed 2025-10-30 |
| 2025-06-30 | $77.19B 10-Q · filed 2025-07-31 |
| 2025-03-31 | $74.98B 10-Q · filed 2025-04-24 |
| 2024-12-31 | $76.22B 10-K · filed 2026-02-11 |
| 2024-09-30 | $76.47B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $77.58B 10-Q · filed 2024-07-26 |
| 2024-03-31 | $82.48B 10-Q · filed 2024-04-25 |
| 2023-12-31 | $65.67B 10-K · filed 2025-02-12 |
| 2023-09-30 | $62.20B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $61.46B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $62.40B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $65.70B 10-K · filed 2024-02-13 |
| 2022-09-30 | $65.46B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $67.70B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $71.39B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $73.31B 10-K · filed 2023-02-14 |
| 2021-09-30 | $73.61B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $73.92B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $74.76B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $80.60B 10-K · filed 2022-02-09 |
| 2020-09-30 | $75.31B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $78.92B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $79.31B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $78.25B 10-K · filed 2021-02-10 |
| 2019-09-30 | $39.68B 10-Q · filed 2019-10-31 |
| 2019-06-30 | $39.01B 10-Q · filed 2019-07-25 |
| 2019-03-31 | $19.52B 10-Q · filed 2019-04-25 |
| 2018-12-31 | $20.86B 10-K · filed 2020-02-24 |
| 2018-09-30 | $19.98B 10-Q · filed 2018-10-25 |
| 2018-06-30 | $20.22B 10-Q · filed 2018-07-26 |
| 2018-03-31 | $20.18B 10-Q · filed 2018-04-26 |
| 2017-12-31 | $21.70B 10-K · filed 2019-02-25 |
| 2017-09-30 | $19.06B 10-Q · filed 2017-10-26 |
| 2017-06-30 | $18.59B 10-Q · filed 2017-07-27 |
| 2017-03-31 | $18.40B 10-Q · filed 2017-04-27 |
| 2016-12-31 | $17.36B 10-K · filed 2018-02-13 |
| 2016-09-30 | $17.95B 10-Q · filed 2016-10-27 |
| 2016-06-30 | $17.75B 10-Q · filed 2016-07-28 |
| 2016-03-31 | $17.34B 10-Q · filed 2016-04-28 |
| 2015-12-31 | $17.32B 10-K · filed 2017-02-21 |
| 2015-09-30 | $16.51B 10-Q · filed 2015-10-27 |
| 2015-06-30 | $16.66B 10-Q · filed 2015-07-23 |
| 2015-03-31 | $17.89B 10-Q · filed 2015-04-28 |
| 2014-12-31 | $18.77B 10-K · filed 2016-02-12 |
| 2014-09-30 | $18.25B 10-Q · filed 2014-10-24 |
| 2014-06-30 | $18.12B 10-Q · filed 2014-07-24 |
| 2014-03-31 | $17.89B 10-Q · filed 2014-04-29 |
| 2013-12-31 | $23.36B 10-K · filed 2015-02-13 |
| 2013-09-30 | $22.09B 10-Q · filed 2013-10-23 |
| 2013-06-30 | $21.88B 10-Q · filed 2013-07-25 |
| 2013-03-31 | $22.26B 10-Q · filed 2013-04-25 |
| 2012-12-31 | $22.26B 10-K · filed 2014-02-14 |
| 2012-09-30 | $22.14B 10-Q · filed 2012-10-24 |
| 2012-06-30 | $15.86B 10-Q · filed 2012-07-25 |
| 2012-03-31 | $16.16B 10-Q · filed 2012-04-26 |
| 2011-12-31 | $17.10B 10-K · filed 2013-02-15 |
| 2011-09-30 | $15.58B 10-Q · filed 2011-10-27 |
| 2011-06-30 | $15.69B 10-Q · filed 2011-07-28 |
| 2011-03-31 | $14.95B 10-Q · filed 2011-04-28 |
| 2010-12-31 | $15.44B 10-K · filed 2012-02-17 |
| 2010-09-30 | $16.03B 10-Q · filed 2010-10-26 |
| 2010-06-30 | $15.48B 10-Q · filed 2010-07-22 |
| 2010-03-31 | $15.52B 10-Q · filed 2010-04-29 |
| 2009-12-31 | $16.22B 10-K · filed 2011-02-18 |
| 2009-09-30 | $16.58B 10-Q · filed 2009-10-22 |
| 2009-06-30 | $15.87B 10-Q · filed 2009-07-23 |
| 2008-12-31 | $17.28B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |